ESR1 and breast cancer: Furthermore, CXCR-4 overexpression may promote the development of BC, recurrence, and resistance to endocrine treatment through an estrogen-independent mechanism and is highly correlated with a poor prognosis and shorter patient survival rates, regardless of ER status [149].